A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma

BACKGROUND: There is no standard first-line therapy for advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma and the prognosis remains poor. Our institution conducted a phase I study of oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule. The regimen was tolera...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Brell, Joanna M., Krishnamurthi, Smitha S., Javle, Milind, Saltzman, Joel, Wollner, Ira, Pelley, Robert, Dowlati, Afshin, Kantharaj, Belagodu N., Schluchter, Mark D., Rath, Linda, Ivy, S. Percy, Remick, Scot C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4209292/
https://ncbi.nlm.nih.gov/pubmed/18670776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-008-0807-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller